Stockscreener 앱 받기
2.09
0.95%
-0.02
시간 외 거래:
2.08
-0.010
-0.48%
Century Therapeutics Inc 주식(IPSC)의 최신 뉴스
Century Therapeutics Inc (IPSC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Century Therapeutics Inc (IPSC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Century Therapeutics Inc (IPSC) Cash Flow - TradingKey
IPSC|Century Therapeutics Inc|Price:2.110|Chg%:-0.060 - TradingKey
Century Therapeutics, Inc. Revenue Breakdown – NASDAQ:IPSC - TradingView
IPSC stock trades steadily as Century Therapeutics updates its pipeline and cash runway - Ad-hoc-news.de
IPSC stock trades around recent lows as Century Therapeutics weighs pipeline and cash burn - Ad-hoc-news.de
Century Therapeutics (IPSC) Dips 2.7% as Shares Near Key Support ZoneDividend Stock Picks - dars.gov.et
Century Therapeutics (IPSC) to Present CNTY-813 Data at Scientific Congresses - Yahoo Finance
Century: 'Hold' Based On CNTY-101 Pivot And CNTY-813 T1D Curative Potential - Seeking Alpha
Century Therapeutics abstracts accepted for diabetes conferences - Investing.com
Century Therapeutics abstracts accepted for diabetes conferences By Investing.com - Investing.com South Africa
Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026 - Investing News Network
Century Therapeutics (IPSC) Q1 2026 Earnings: Narrower Loss Surprises, Shares ClimbEarnings Growth Analysis - dars.gov.et
Frontier tech research, news & data - MLQ.ai
IPSC Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Stock ReactionEstimate Dispersion - dars.gov.et
IPSCCentury Therapeutics Inc Short Interest - Finviz
Price to sales forward of Century Therapeutics, Inc. – NASDAQ:IPSC - TradingView
IPSC News | CENTURY THERAPEUTICS INC (NASDAQ:IPSC) - ChartMill
Century Therapeutics, Inc.(NasdaqCM: IPSC) added to Russell 2000 Index - marketscreener.com
Century Therapeutics, Inc.(NasdaqCM: IPSC) added to Russell 2000 Value Benchmark - marketscreener.com
Century Therapeutics, Inc.(NasdaqCM:IPSC) added to Russell Microcap Value Benchmark Index - marketscreener.com
Century Therapeutics, Inc.(NasdaqCM: IPSC) added to Russell Microcap Index - marketscreener.com
Century Therapeutics (IPSC) Holds Support With Modest Gain Amid Biotech Sector UncertaintyVirgin POC - dars.gov.et
Century Therapeutics, Inc. Actuals & Estimates (NASDAQ:IPSC) - TradingView
Enterprise value to EBIT forward of Century Therapeutics, Inc. – NASDAQ:IPSC - TradingView
Price to earnings forward of Century Therapeutics, Inc. – NASDAQ:IPSC - TradingView
IPSC Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Century Therapeutics, Inc. – NASDAQ:IPSC - TradingView
Century Therapeutics updates its CAR-T pipeline, shares trade on Nasdaq - Ad-hoc-news.de
Century Therapeutics Inc (IPSC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight - GlobeNewswire Inc.
Century Therapeutics Inc. (IPSC) Edges Higher as Biotech Stock Tests Key Resistance ZoneGap and Go - dars.gov.et
Century Therapeutics Inc (IPSC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Century Therapeutics Inc (IPSC) Institutional Confidence - TradingKey
Century Therapeutics Inc (IPSC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Century Therapeutics Inc (IPSC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Century Therapeutics Inc (IPSC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Century Therapeutics Inc (IPSC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Century Therapeutics amends chief scientific officer contract to part-time role By Investing.com - Investing.com South Africa
Century Therapeutics amends chief scientific officer contract to part-time role - Investing.com India
Century retains Chad Cowan as part-time Chief Scientific Officer with reduced pay - TradingView
Century Therapeutics (IPSC) shifts Chief Scientific Officer to part-time role with new pay terms - Stock Titan
Century Therapeutics SVP Carr sells $3,691 in company stock By Investing.com - Investing.com India
Century Therapeutics SVP Carr sells $3,691 in company stock - Investing.com
Century Therapeutics executive Gregory Russotti sells $5,767 in stock By Investing.com - Investing.com Nigeria
Century Therapeutics executive Gregory Russotti sells $5,767 in stock - Investing.com
Century Therapeutics (IPSC) executive sells shares to cover RSU tax withholding - Stock Titan
Tax-related share sale by Century Therapeutics (IPSC) SVP Carr - Stock Titan
Century Therapeutics (IPSC) CEO reports 13,849-share tax withholding on RSU vesting - Stock Titan
Century Therapeutics (IPSC) CSO reports tax withholding of shares and restated holdings - Stock Titan
Century Therapeutics Shareholders Approve Directors and Share Increase - The Globe and Mail
Here's Why We're Watching Century Therapeutics' (NASDAQ:IPSC) Cash Burn Situation - Yahoo Finance
Century Therapeutics (IPSC) director Alessandro Riva granted 74,000 stock options - Stock Titan
Director Daphne Quimi receives 74,000 stock options at Century Therapeutics (NASDAQ: IPSC) - Stock Titan
1.97%
0.83%
자본화:
|
볼륨(24시간):